Which of the following provides symptomatic relief in a patient diagnosed with myasthenia gravis?

In myasthenia gravis, a neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles, symptomatic relief is often achieved through the use of specific medications that enhance neuromuscular transmission. Oral pyridostigmine is an acetylcholinesterase inhibitor that increases the availability of acetylcholine at the neuromuscular junction, thereby improving muscular strength and reducing fatigue. By inhibiting the breakdown of acetylcholine, pyridostigmine helps to counteract the underlying defect in transmission seen in myasthenia gravis, leading to noticeable symptomatic relief for patients.

This targeted mechanism makes oral pyridostigmine a first-line treatment for managing symptoms in myasthenia gravis. It directly addresses the problem of muscle weakness by enhancing neurotransmission. In contrast, while corticosteroids and immunosuppressive therapy are important for long-term management to reduce autoimmune activity, they do not provide immediate symptomatic relief as effectively as pyridostigmine does.

Thyroid hormone replacement is not relevant in the context of myasthenia gravis unless there is coexisting thyroid dysfunction that needs to be treated, as it does not directly alleviate muscle weakness associated with the condition. Thus, pyridost